Literature DB >> 22566277

Prediction of pathologic response to neoadjuvant chemotherapy in patients with breast cancer using diffusion-weighted imaging and MRS.

Hee Jung Shin1, Hyeon-Man Baek, Jin-Hee Ahn, Seunghee Baek, Hyunji Kim, Joo Hee Cha, Hak Hee Kim.   

Abstract

The aim of this study was to determine whether tumor size, MRS parameters and apparent diffusion coefficient (ADC) measurements could be applied to predict pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC). Ninety patients with breast cancer (median size, 4.5 cm; range, 1.6-9.5 cm) were evaluated with single-voxel ¹H MRS and dynamic contrast-enhanced MRI. Diffusion-weighted imaging was performed in 41 of these patients using a 1.5-T scanner before and after completion of NAC. Pre- and post-treatment measurements and changes in tumor size, MRS parameters [absolute and normalized total choline-containing compound (tCho) integral and tCho signal-to-noise ratio (SNR)] and ADCs in pCR versus non-pCR were compared using the nonparametric Mann-Whitney test. Receiver operating characteristic (ROC) curve analysis was performed to assess the diagnostic performance of each parameter. After NAC, 30 patients (33%) showed pCR and 60 (67%) showed non-pCR. At pretreatment, ADC was the only significant parameter in differentiating between pCR and non-pCR [(0.83 ± 0.05) × 10⁻³ versus (0.97 ± 0.14) × 10⁻³ mm²/s] (p = 0.014). Post-treatment measurements after completion of NAC and changes in tumor size (both p < 0.001), MRS parameters (p = 0.027 and p = 0.020 for absolute tCho integral, p = 0.036 and p = 0.023 for normalized tCho integral, and p = 0.032 and p = 0.061 for tCho SNR) and ADC (p = 0.003 and p < 0.001) were significantly different between the pCR and non-pCR groups, except for changes in tCho SNR. In ROC analysis, the areas under the ROC curve (AUCs) of 0.63-0.73 were obtained for tumor size and MRS parameters. AUCs for pre- and post-treatment ADC and changes in ADC were 0.75, 0.80 and 0.96, respectively. The optimal cut-off of the percentage change in ADC for predicting pCR was 40.7%, yielding 100% sensitivity and 91% specificity. Patients with pCR showed significantly lower pretreatment ADCs than those with non-pCR. The change in ADC after NAC was the most accurate predictor of pCR.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22566277     DOI: 10.1002/nbm.2807

Source DB:  PubMed          Journal:  NMR Biomed        ISSN: 0952-3480            Impact factor:   4.044


  24 in total

1.  Study of tumour cellularity in locally advanced breast carcinoma on neo-adjuvant chemotherapy.

Authors:  Swarup Kumar; Bhawana Ashok Badhe; K M Krishnan; Haritha Sagili
Journal:  J Clin Diagn Res       Date:  2014-04-15

Review 2.  Skeletal Muscle Quantitative Nuclear Magnetic Resonance Imaging and Spectroscopy as an Outcome Measure for Clinical Trials.

Authors:  Pierre G Carlier; Benjamin Marty; Olivier Scheidegger; Paulo Loureiro de Sousa; Pierre-Yves Baudin; Eduard Snezhko; Dmitry Vlodavets
Journal:  J Neuromuscul Dis       Date:  2016-03-03

Review 3.  Imaging Considerations and Interprofessional Opportunities in the Care of Breast Cancer Patients in the Neoadjuvant Setting.

Authors:  Anna G Sorace; Sara Harvey; Anum Syed; Thomas E Yankeelov
Journal:  Semin Oncol Nurs       Date:  2017-09-15       Impact factor: 2.315

4.  Targeted imaging of breast tumor progression and therapeutic response in a human uMUC-1 expressing transgenic mouse model.

Authors:  Subrata K Ghosh; Masashi Uchida; Byunghee Yoo; Alana W Ross; Sandra J Gendler; Jianlin Gong; Anna Moore; Zdravka Medarova
Journal:  Int J Cancer       Date:  2012-10-25       Impact factor: 7.396

5.  Current and emerging quantitative magnetic resonance imaging methods for assessing and predicting the response of breast cancer to neoadjuvant therapy.

Authors:  Richard G Abramson; Lori R Arlinghaus; Jared A Weis; Xia Li; Adrienne N Dula; Eduard Y Chekmenev; Seth A Smith; Michael I Miga; Vandana G Abramson; Thomas E Yankeelov
Journal:  Breast Cancer (Dove Med Press)       Date:  2012-10

Review 6.  Therapy response with diffusion MRI: an update.

Authors:  Lauren J Bains; Martin Zweifel; Harriet C Thoeny
Journal:  Cancer Imaging       Date:  2012-09-28       Impact factor: 3.909

7.  Treatment Response Evaluation of Breast Cancer after Neoadjuvant Chemotherapy and Usefulness of the Imaging Parameters of MRI and PET/CT.

Authors:  Yeong Yi An; Sung Hun Kim; Bong Joo Kang; Ah Won Lee
Journal:  J Korean Med Sci       Date:  2015-05-13       Impact factor: 2.153

8.  Diffusion-weighted MRI for predicting pathologic response to neoadjuvant chemotherapy in breast cancer: evaluation with mono-, bi-, and stretched-exponential models.

Authors:  Shiteng Suo; Yan Yin; Xiaochuan Geng; Dandan Zhang; Jia Hua; Fang Cheng; Jie Chen; Zhiguo Zhuang; Mengqiu Cao; Jianrong Xu
Journal:  J Transl Med       Date:  2021-06-02       Impact factor: 5.531

9.  The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review.

Authors:  M B I Lobbes; R Prevos; M Smidt; V C G Tjan-Heijnen; M van Goethem; R Schipper; R G Beets-Tan; J E Wildberger
Journal:  Insights Imaging       Date:  2013-01-29

10.  Early prediction of response to neoadjuvant chemotherapy in patients with breast cancer using diffusion-weighted imaging and gray-scale ultrasonography.

Authors:  Hitomi Iwasa; Kei Kubota; Norihiko Hamada; Munenobu Nogami; Akihito Nishioka
Journal:  Oncol Rep       Date:  2014-02-18       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.